Effect of Social Media Support and Financial Incentives on PrEP Adherence

The Effect of Social Media Support and Financial Incentives on Adherence to HIV Pre-exposure Prophylaxis in Young MSM of Color in Washington, DC

The purpose of this study is to determine if social media support and financial incentives improve adherence to Truvada as PrEP in African American, Latino and Asian MSM aged 18 to 24 living in the Washington, DC area who are at high risk for HIV acquisition.

Study Overview

• Status: Completed
• Conditions: Pre-Exposure Prophylaxis
• Intervention / Treatment: Behavioral: Financial Incentive; Behavioral: Social Media Group

• Study Type: Interventional
• Enrollment (Actual): 57
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • District of Columbia
    • Washington, District of Columbia, United States, 20037
      • The GW Medical Faculty Associates

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 24 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Male assigned at birth (regardless of current gender identity)
• Age 18-24
• Black/African American, Latino or Asian
• HIV negative
• History of unprotected anal sex with a man in the last 6 months
• Living within the DC metropolitan statistical area and anticipate remaining within the DC area for the next 6 months
• Not enrolled in any other HIV prevention trial
• Interested in taking PrEP
• Not a current PrEP user and have not taken PrEP in the last 30 days
• Able to provide informed consent

Exclusion Criteria:

• Female sex at birth
• Age younger than 18 or older than 24
• Caucasian
• HIV positive
• Actively taking PrEP or having taken PrEP within 30 days of enrollment
• Chronic hepatitis B infection
• Known renal insufficiency
• On probation or parole
• Any other conditions that the Principal Investigator may consider a contraindication to enrolling in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Control; No intervention
Experimental: Financial Incentive; Provided financial incentive at 3-month and 6-month follow-up visits	Behavioral: Financial Incentive; Participants will receive a $50 gift card at 3- and 6- month follow-up visits.
Experimental: Social Media Group; Provided social media support through a facebook group for 6 months	Behavioral: Social Media Group; Participants will be invited to a study Facebook group which will have links to PrEP information and provide a forum for participants to ask questions and communicate their experience with PrEP

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adherence To Truvada	Level of Truvada drug levels inside red blood cells (performed by dried blood spots)	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
New Cases of HIV	Number of reactive HIV rapid and 4th generation tests	6 months
Incidence of STIs	Positive RPR, oropharyngeal/rectal/penile chlamydia and gonorrhea during study	6 months

Collaborators and Investigators

• Sponsor: George Washington University
• Collaborators: National Institute of Allergy and Infectious Diseases (NIAID); Gilead Sciences
• Investigators: Principal Investigator: Marc Siegel, MD, The GW Medical Faculty Associates

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2017
• Primary Completion (Actual): December 15, 2020
• Study Completion (Actual): December 15, 2020

Study Registration Dates

• First Submitted: March 7, 2017
• First Submitted That Met QC Criteria: March 7, 2017
• First Posted (Actual): March 13, 2017

Study Record Updates

• Last Update Posted (Actual): February 2, 2021
• Last Update Submitted That Met QC Criteria: February 1, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Other Study ID Numbers: 111642; 1P30AI117970 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No